AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17927576 — intervention group
Group type: COMPARATOR
Intervention: Retinoic acid therapy
Number of subjects: 0
Study 15784032 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg, three times daily for 6 months)
Number of subjects: 112
Study 15784032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearance to indomethacin, for 6 months)
Number of subjects: 112
Study 15784032 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 112
Study 15784032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 12487503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusafungine
Number of subjects: 81
Study 12487503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10323814 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from alcohol consumption for 1 month before operation (disulfiram controlled)
Number of subjects: 42
Study 10323814 — intervention group
Group type: COMPARATOR
Intervention: Continuous drinking
Number of subjects: 42
Study 8942899 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited SMAS (lateral SMASectomy)
Number of subjects: 21
Study 8942899 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional SMAS
Number of subjects: 21
Study 8942899 — intervention group
Group type: COMPARATOR
Intervention: Extended SMAS
Number of subjects: 21
Study 8942899 — intervention group
Group type: COMPARATOR
Intervention: Composite rhytidectomy
Number of subjects: 21
Study 1754846 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS), two tablets twice daily for 4 weeks
Number of subjects: 71
Study 1754846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 1754846 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 71
Study 7022484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (300 mg per day)
Number of subjects: 317
Study 7022484 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g per day)
Number of subjects: 317
Study 7022484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 31977643 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Loading (ITL)
Number of subjects: 12
Study 31977643 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Flexion (INF)
Number of subjects: 12
Study 31188026 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 53
Study 31188026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 28951663 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg i.v. ibuprofen
Number of subjects: 42
Study 28951663 — intervention group
Group type: COMPARATOR
Intervention: saline without ibuprofen
Number of subjects: 42
Study 27290966 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil infusion
Number of subjects: 30
Study 27290966 — intervention group
Group type: COMPARATOR
Intervention: Low-dose remifentanil infusion
Number of subjects: 30
Study 24418652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 101
Study 24418652 — intervention group
Group type: COMPARATOR
Intervention: Community Treatment by Experts (CTBE)
Number of subjects: 101
Study 22954842 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE) administered for 10 treatment sessions over 5 weeks
Number of subjects: 0
Study 22954842 — intervention group
Group type: COMPARATOR
Intervention: Minimal Attention (MA) control group for 5 weeks
Number of subjects: 0
Study 22954842 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study 19651336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.016-in CuNiTi wire
Number of subjects: 60
Study 19651336 — intervention group
Group type: COMPARATOR
Intervention: 0.016-in NiTi wire
Number of subjects: 60
Study 19651336 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe crowding (>5 on the irregularity index)
Number of subjects: 60
Study 16824689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent smokers
Number of subjects: 44
Study 16824689 — intervention group
Group type: COMPARATOR
Intervention: Satiated smokers
Number of subjects: 44
Study 16824689 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 44
Study 16824689 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative clips
Number of subjects: 44
Study 15058627 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled delivery of local anesthetic (AMSA injection)
Number of subjects: 20
Study 15058627 — intervention group
Group type: COMPARATOR
Intervention: Syringe delivery of local anesthetic (GP and NP injections)
Number of subjects: 20
Study 12514752 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest sonography
Number of subjects: 55
Study 12514752 — intervention group
Group type: COMPARATOR
Intervention: Ventilation/perfusion scintigraphy
Number of subjects: 55
Study 9801179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron hydrochloride, 4 mg intravenously
Number of subjects: 78
Study 9801179 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine maleate, 10 mg intramuscularly
Number of subjects: 78
Study 8752413 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringo-subarachnoid shunt (S-S shunt)
Number of subjects: 80
Study 8752413 — intervention group
Group type: COMPARATOR
Intervention: Foramen magnum decompression (FMD)
Number of subjects: 80
Study 2243259 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal health status reports every 3 months over 1 year
Number of subjects: 1920
Study 2243259 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 1920
Study 2243259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1920
Study 345336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine added to contrast medium
Number of subjects: 28
Study 345336 — intervention group
Group type: COMPARATOR
Intervention: Contrast medium alone
Number of subjects: 28
Study 31987233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (0.5 ml of oral 24% sucrose)
Number of subjects: 120
Study 31987233 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (lullaby music)
Number of subjects: 120
Study 31987233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sucrose and music
Number of subjects: 120
Study 31987233 — intervention group
Group type: COMPARATOR
Intervention: Control (headphones without music and sterile water)
Number of subjects: 120
Study 30478984 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Zoom WhiteSpeed (PZW)
Number of subjects: 135
Study 30478984 — intervention group
Group type: COMPARATOR
Intervention: Ultradent Opalescence Boost PF (UOB)
Number of subjects: 135
Study 30478984 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare power toothbrush (SDC)
Number of subjects: 135
Study 30478984 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 135
Study 26691576 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive sarcosine (2 g/day) plus benzoate (1 g/day)
Number of subjects: 0
Study 26691576 — intervention group
Group type: COMPARATOR
Intervention: Sarcosine (2 g/day)
Number of subjects: 0
Study 25291409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.25 mg/kg/d for 7 days
Number of subjects: 198
Study 25291409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 198
Study 22652007 — intervention group
Group type: COMPARATOR
Intervention: GTR-DFDBA
Number of subjects: 12
Study 22652007 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 12
Study 21541462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccine administration (4 mg/dose)
Number of subjects: 31
Study 21541462 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccine administration (40 mg/dose)
Number of subjects: 31
Study 21541462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccine administration
Number of subjects: 31
Study 21541462 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccine administration
Number of subjects: 31
Study 19516157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance and strength training (ES)
Number of subjects: 93
Study 19516157 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 93
Study 19516157 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 93
Study 19516157 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 93
Study 17503990 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 56
Study 17503990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15521845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 18
Study 15521845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg daily
Number of subjects: 57
Study 11419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg every third day
Number of subjects: 57
Study 11419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg every third day
Number of subjects: 57
Study 11419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 40 mg every third day
Number of subjects: 57
Study 11419884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9642312 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 957
Study 9642312 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent use of multiple antipsychotic agents
Number of subjects: 957
Study 9642312 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided daily doses of antipsychotics
Number of subjects: 957
Study 9642312 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of antipsychotic and antiparkinson drugs
Number of subjects: 957
Study 9642312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription patterns between acute and chronic patients
Number of subjects: 957
Study 8329267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single twitch stimulation at 0.1 Hz
Number of subjects: 0
Study 8329267 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation at 2 Hz
Number of subjects: 0
Study 3539708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine therapy (150 mg bd)
Number of subjects: 40
Study 3539708 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 40
Study 30463324 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d Sensoril® (S500)
Number of subjects: 38
Study 30463324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study 27676151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 14
Study 27676151 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Exercise (CE)
Number of subjects: 14
Study 24246116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (20-60mg/d)
Number of subjects: 0
Study 24246116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (80-120mg/d)
Number of subjects: 0
Study 24246116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy (20-120mg/d)
Number of subjects: 0
Study 24246116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy and adjunctive therapy
Number of subjects: 0
Study 24246116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22314520 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic conductivity device (ECD)
Number of subjects: 42
Study 22314520 — intervention group
Group type: COMPARATOR
Intervention: Normal pedicle finder (NPF)
Number of subjects: 42
Study 20569447 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.5 mg/kg/day)
Number of subjects: 157
Study 20569447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 17709207 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (75 mg)
Number of subjects: 17
Study 17709207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 17
Study 17709207 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen (325 mg) and tramadol (37.5 mg)
Number of subjects: 17
Study 17709207 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 17
Study 12375302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine intervention
Number of subjects: 0
Study 9438767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1 mg/kg of body weight per hour; maximum, 1800 mg/d)
Number of subjects: 51
Study 9438767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 51
Study 9438767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 51
Study 9438767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8586774 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium-enriched Step I diet (3.2 g of soluble fiber per 1-oz box of cereal, 2 boxes per day)
Number of subjects: 50
Study 8586774 — intervention group
Group type: COMPARATOR
Intervention: Step I control diet (less than 0.5 g of soluble fiber per 1-oz box of cereal, 2 boxes per day)
Number of subjects: 50
Study 2770272 — intervention group
Group type: COMPARATOR
Intervention: Stationary cycle (C)
Number of subjects: 5
Study 2770272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rower (R)
Number of subjects: 5
Study 2770272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski simulator (S)
Number of subjects: 5
Study 2770272 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill (walking) (T)
Number of subjects: 5
Study 790146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy in a protected environment unit with antibiotic prophylaxis
Number of subjects: 13
Study 790146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy in a protected environment unit without antibiotic prophylaxis
Number of subjects: 13
Study 790146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy out of a protected environment unit with antibiotic prophylaxis
Number of subjects: 13
Study 790146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy out of a protected environment unit without antibiotic prophylaxis
Number of subjects: 13
Study 790146 — intervention group
Group type: EXPERIMENTAL
Intervention: Early consolidation therapy
Number of subjects: 13
Study 790146 — intervention group
Group type: COMPARATOR
Intervention: Conventional maintenance therapy
Number of subjects: 13
Study 28323986 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intranasal insulin treatment (40 IU, 4 times daily)
Number of subjects: 20
Study 28323986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25813656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily (OaD)
Number of subjects: 423
Study 25813656 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil on-demand (PRN)
Number of subjects: 423
Study 25813656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 23404788 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg (10 mg for first 4 weeks)
Number of subjects: 305
Study 23404788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 21207158 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 40
Study 21207158 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 40
Study 21207158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laparoscopic and open resection
Number of subjects: 40
Study 20443395 — intervention group
Group type: EXPERIMENTAL
Intervention: Videophone communication (Skype) for 30 minutes once a week for 12 weeks
Number of subjects: 13
Study 20443395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no videophone communication)
Number of subjects: 13
Study 16979854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory‐motor‐oral stimulation and non‐nutritive sucking
Number of subjects: 98
Study 16979854 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation program
Number of subjects: 98
Study 14757395 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care assistants providing additional feeding support
Number of subjects: 592
Study 14757395 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without additional feeding support)
Number of subjects: 592
Study 11699736 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B children's power toothbrush (D10)
Number of subjects: 70
Study 11699736 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 70
Study 9446408 — intervention group
Group type: EXPERIMENTAL
Intervention: p21ras protein accumulation in tumors
Number of subjects: 80
Study 9446408 — intervention group
Group type: COMPARATOR
Intervention: p21ras protein accumulation
Number of subjects: 80
Study 8199828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations with immuno‐ or chemotherapy
Number of subjects: 387
Study 8199828 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of tumour in high risk regions (prostatic urethra, bladder neck, posterior wall, trigone area)
Number of subjects: 387
Study 8199828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour multiplicity
Number of subjects: 387
Study 8199828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour stage
Number of subjects: 387
Study 8199828 — intervention group
Group type: COMPARATOR
Intervention: Gender, age, history of recurrent disease, size of the largest tumour, tumour stage or grade
Number of subjects: 387
Study 3592311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed grass extract
Number of subjects: 60
Study 3592311 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified timothy pollen
Number of subjects: 60
Study 3592311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine‐bound mixture
Number of subjects: 60
Study 31387606 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg
Number of subjects: 1957
Study 31387606 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg
Number of subjects: 1957
Study 31387606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1957
Study 28784336 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestrogen daily (low-dose group)
Number of subjects: 121
Study 28784336 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg oestrogen daily (high-dose group)
Number of subjects: 121
Study 25305042 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO
Number of subjects: 36
Study 25305042 — intervention group
Group type: EXPERIMENTAL
Intervention: BRVO
Number of subjects: 36
Study 25305042 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 23064871 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity eccentric contractions (10 %ECC)
Number of subjects: 26
Study 23064871 — intervention group
Group type: COMPARATOR
Intervention: Maximal eccentric contractions (MaxECC)
Number of subjects: 26
Study 21229331 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) with a threshold device (40% of maximum inspiratory pressure, MIP) for 30 min/day from the 2nd to the 30th postoperative day
Number of subjects: 30
Study 21229331 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 30
Study 19121500 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivally offset mandibular premolar brackets
Number of subjects: 83
Study 19121500 — intervention group
Group type: COMPARATOR
Intervention: Standard mandibular premolar brackets
Number of subjects: 83
Study 16477259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) levels across quintiles
Number of subjects: 4231
Study 15140632 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0-10 mg/70 kg, p.o.)
Number of subjects: 7
Study 15140632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (0-60 mg/70 kg, p.o.)
Number of subjects: 7
Study 15140632 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine combined with naloxone
Number of subjects: 7
Study 15140632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan combined with naloxone
Number of subjects: 7
Study 15140632 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.15 mg/70 kg, i.m.)
Number of subjects: 7
Study 12017799 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3) combined with dimethyl isosorbide (DMI)
Number of subjects: 0
Study 12017799 — intervention group
Group type: COMPARATOR
Intervention: Potassium nitrate (KNO3) alone
Number of subjects: 0
Study 9868127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 44
Study 9868127 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 8194687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine enemas (350 mg nightly for 4 weeks)
Number of subjects: 40
Study 8194687 — intervention group
Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 40
Study 3037899 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 206
Study 3037899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 3037899 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin‐polymyxin
Number of subjects: 206
Study 3037899 — intervention group
Group type: COMPARATOR
Intervention: TMP/SMX
Number of subjects: 206
Study 3037899 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 206
Study 31302767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during the whole course of cytotoxic agents administration (arm A)
Number of subjects: 145